<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753541</url>
  </required_header>
  <id_info>
    <org_study_id>304/20 S-KH</org_study_id>
    <nct_id>NCT04753541</nct_id>
  </id_info>
  <brief_title>The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation.</brief_title>
  <acronym>AF GEN</acronym>
  <official_title>Untersuchung Des Einflusses Von Genetischem Risiko Auf Den Erfolg Einer Katheterablation Bei Paroxysmalem Und Persistierendem Vorhofflimmern</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catheter ablation is an established standard therapy in interventional treatment of atrial&#xD;
      fibrillation.The trial investigates the influence of genetic risk for the recurrence of&#xD;
      atrial fibrillation after catheter ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Catheter ablation is an established standard therapy in interventional treatment of atrial&#xD;
      fibrillation. electric isolation of the pulmonary veins, from which atrial fibrillation is&#xD;
      originating in most patients, is cornerstone of all atrial fibrillation patients.&#xD;
&#xD;
      The most common cause for AF recurrence is still incomplete isolation of the pulmonary veins,&#xD;
      on the other hand, only 80% of paroxysmal and 60 % of persistent patients can successfully be&#xD;
      cured from atrial fibrillation (despite of isolated pulmonary veins after multiple ablation&#xD;
      procedures).&#xD;
&#xD;
      By now, non-procedure related predictive risk factors, resulting in recurrence of atrial&#xD;
      fibrillation after catheter ablation, are only partially identified, such as obesity,&#xD;
      hypertension and sleep apnea.&#xD;
&#xD;
      In the past year several genetic risk alleles were identified, which are associated with&#xD;
      atrial fibrillation. By now the relation between genetic risk, which is determined for every&#xD;
      patient by its specific genotype and the outcome of catheter ablation in paroxysmal and&#xD;
      persistent atrial fibrillation has not yet been investigated.&#xD;
&#xD;
      The aim is to investigate the influence of genetic risk for the recurrence of atrial&#xD;
      fibrillation after catheter ablation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Influence of genetic risk on atrial fibrillation</measure>
    <time_frame>10ml blood sample taken at baseline visit (routine blood sample)</time_frame>
    <description>Analysation of the influence of genetic risk on the probability of recurrence of atrial fibrillation after catheter ablation</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>this is not an interventional study</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10 ml EDTA-blood routine samples taken will be analysed for risk allele loci associated with&#xD;
      atrial fibrillation&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients planned for primary ablation due to paroxysmale or persistent atrial fibrillation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients planned for primary ablation due to paroxysmale or persistent atrial&#xD;
             fibrillation&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients under 18 years of age or patients not able to give informed consent&#xD;
&#xD;
          -  prior left atrial ablation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bourier Felix, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum MÃ¼nchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felix Bourier, MD</last_name>
    <phone>+49891218</phone>
    <phone_ext>2020</phone_ext>
    <email>bourier@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heike Starkmann</last_name>
    <phone>+49891218</phone>
    <phone_ext>1192</phone_ext>
    <email>starkmannh@dhm.mhn.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Deisenhofer, MD</last_name>
      <phone>+49 89 1218 2020</phone>
      <email>deisenhofer@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Isabel Deisenhofer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

